<DOC>
	<DOCNO>NCT01148017</DOCNO>
	<brief_summary>The primary objective evaluate persistence bactericidal antibodies child 40 60 month age previously enrol V59P14 ( NCT00474526 ) study receive Novartis MenACWY Conjugate Vaccine . The study also enrol age-matched subject never receive meningococcal vaccine ( na誰ve subject ) serve control group . In addition , response booster dose 60 month evaluate .</brief_summary>
	<brief_title>Evaluation Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children eligible enrol study whose parent provide write informed consent , generally good health base clinical judgment investigator . Group 1 2 ( Follow ) subject must 40 +/ 3 month age time enrollment participate original V59P14 study ( NCT00474526 ) . Group 3 4 ( Na誰ve ) subject must healthy , meningococcal vaccinena誰ve child age 40 +/ 3 month ( Group 3 ) 60 +/3 month ( Group 4 ) time enrollment , respectively . Serious , acute , chronic illness reason exclusion . Subjects receive vaccine ( exclude influenza vaccine ) 28 day precede enrollment visit . Influenza vaccine ( include FluMist速 ) exclude 14 day prior enrollment visit . Subjects received meningococcal vaccine since birth ( Groups 3 &amp; 4 naive ) last study dose V59P14 ( NCT00474526 ) trial ( Groups 1 &amp; 2 follow ) .</criteria>
	<gender>All</gender>
	<minimum_age>37 Months</minimum_age>
	<maximum_age>63 Months</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Meningococcal</keyword>
	<keyword>ACWY</keyword>
	<keyword>Conjugate Vaccine</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Children</keyword>
	<keyword>Persistence</keyword>
	<keyword>Booster dose</keyword>
</DOC>